HANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA

Stock News

昨天

HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1190790439"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190790439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190790439?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190790439","market":"us","top_or_hot":-1,"title":"HANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA","media":"Stock News","content":"<p>HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-16 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"","article_id":"1190790439","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190790439","pubTimestamp":1776339378,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药"},"translate_title":"翰森制药自研B7-H3靶向ADC HS-20093联合阿德贝利木单抗获NMPA突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}